文献速递肿瘤 PET/CT核素与放射性配体治疗

基线FDG PET/CT总代谢肿瘤体积联合基因表达谱对弥漫大B细胞淋巴瘤患者具有稳健的预测价值

Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-01-17

纳入114例接受R-CHOP或R-CHOP样化疗的弥漫大B细胞淋巴瘤患者,基线FDG PET/CT以41% SUVmax阈值测量总代谢肿瘤体积(TMTV),并用快速逆转录多重连接依赖探针扩增(RT-MLPA)进行基因表达分型。中位随访40个月,TMTV最佳截断值261 cm3,高TMTV组5年无进展生存(PFS)和总生存(OS)均低于低TMTV组,TMTV联合ABC/GCB分型可区分三组预后差异显著的患者。

要点

  • TMTV最佳截断值为261 cm3,高TMTV组59例5年PFS 37%、OS 39%,低TMTV组55例分别为72%、83%。
  • ABC亚型较高TMTV联合分子分型分出三组:低TMTV任何表型55例5年PFS 72%、OS 83%;高TMTV且GCB型33例5年PFS 51%、OS 55%;高TMTV且ABC型26例5年PFS 17%、OS 17%。
  • 多因素分析中TMTV、ABC/GCB表型和国际预后指数均为PFS和OS的独立预测因素(两者p<0.05)。

核心结论

  • 该整合风险模型可能有助于更准确地筛选患者,从而实现更好的个体化治疗。

研究设计与样本

  • 纳入114例接受R-CHOP或R-CHOP样化疗的弥漫大B细胞淋巴瘤患者,基线FDG PET/CT以41% SUVmax阈值测量TMTV,并用RT-MLPA进行基因表达分型。

主要发现

  • 中位随访40个月,5年PFS为54%,5年OS为62%。
  • TMTV最佳截断值为261 cm3;高TMTV组59例5年PFS 37%、OS 39%,低TMTV组55例5年PFS 72%、OS 83%(PFS p=0.0002,OS p<0.0001)。
  • ABC状态与更差预后显著相关。
  • TMTV联合分子数据识别出三组结局差异显著的患者:低TMTV任何表型组(n=55)、高TMTV且GCB表型组(n=33)、高TMTV且ABC表型组(n=26),三组5年PFS分别为72%、51%、17%(p<0.0001),5年OS分别为83%、55%、17%(p<0.0001)。
  • 多因素分析中TMTV、ABC/GCB表型和国际预后指数均为PFS和OS的独立预测因素(两者p<0.05)。

关键数值与推荐

  • TMTV测量采用41% SUVmax阈值。
  • TMTV最佳截断值为261 cm3。
  • 根据RT-MLPA测定将肿瘤分为GCB或ABC亚型。

临床怎么用

  • 原文结论认为该整合风险模型可能有助于更准确地筛选患者,从而实现更好的个体化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated the predictive significance of total metabolic tumour volume (TMTV) measured on baseline FDG PET/CT and its value in addition to gene expression profiling using a new method of gene analysis (rapid reverse transcriptase multiplex ligation-dependent probe amplification assay, RT-MLPA) in patients with diffuse large B-cell lymphoma treated with R-CHOP or R-CHOP-like chemotherapies. METHODS: The analysis included 114 patients. TMTV was measured using a 41% SUVmax threshold and tumours were classified into GCB or ABC subtypes according to the RT-MLPA assay. RESULTS: The median follow-up was 40 months. the 5-year progression-free survival (PFS) was 54% and the 5-year overall survival (OS) was 62%. The optimal TMTV cut-off value was 261 cm3. In 59 patients with a high TMTV the 5-year PFS and OS were 37% and 39%, respectively, in comparison with 72% and 83%, respectively, in 55 patients with a low TMTV (p = 0.0002 for PFS, p < 0.0001 for OS). ABC status was significantly associated with a worse prognosis. TMTV combined with molecular data identified three groups with very different outcomes: (1) patients with a low TMTV whatever their phenotype (n = 55), (2) patients with a high TMTV and GCB phenotype (n = 33), and (3) patients with a high TMTV and ABC phenotype (n = 26). In the three groups, 5-year PFS rates were 72%, 51% and 17% (p < 0.0001), and 5-year OS rates were 83%, 55% and 17% (p < 0.0001), respectively. In multivariate analysis, TMTV, ABC/GCB phenotype and International Prognostic Index were independent predictive factors for both PFS and OS (p < 0.05 for both). CONCLUSIONS: This integrated risk model could lead to more accurate selection of patients that would allow better individualization of therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Toledano MN, Desbordes P, Banjar A, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 29344718. doi:10.1007/s00259-017-3907-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。